Active substance
Vincristine
- SFDA 6
- US FDA 18
- Health Canada 2
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VINCRISTIN SULPH. 1MG-ML VIAL | 1 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 159.80 | Generic · Prescription | HOSPIRA UK LIMITED | Valid |
| VINCRISTIN SULPH. 1MG-ML VIAL | 1 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 244.45 | Generic · Prescription | HOSPIRA UK LIMITED | Valid |
| VINBLASTINE SULPHATE 10MG-10ML VIAL | 1 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 223.75 | Generic · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| VINCRISTIN SULPH. 1MG-ML VIAL | 1 mg/ml | Solution · Intravenous use | 5 Vial | SAR 244.45 | Generic · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| VINCRISTIN SULPH. 1MG-ML VIAL | 1 mg/ml | Solution · Intravenous use | 5 Vial | SAR 159.80 | Generic · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| VINCRISTINE ROGER BELLON 1MG-VIAL | 1 mg | Solution · Intravenous use | 1 Vial | SAR 39.70 | Generic · Prescription | SANOFI WINTHROP INDUSTRIE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ADULT ACUTE LYMPHOCYTIC LEUKEMIA (ALL); BONE SARCOMAS; BRAIN CANCERS; BURKITT`S LYMPHOMA; CASTLEMAN DISEASE; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HODGKIN'S LYMPHOMA; IMMUNE THROMBOCYPTOPENIC PUPURA; LYMPHOPLASMACYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; Neuroblastoma; Neurofibromatosis Type 1 - Optic Pathway Glioma; PEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL); PEDIATRIC B-CELL LYMPHOMA; RETINOBLASTOMA; SMALL CELL LUNG CANCER (SCLC); SOFT TISSUE SARCOMA - RHABDOMYOSARCOMA; T-CELL LYMPHOMA; THROMBOTIC THROMBOCYTOPENIC PURPURA; WILMS TUMOR
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VINCRISTINE SULFATE PFS | 1MG/ML | injectable · injection | HOSPIRA | Prescription | 19 Apr 1988 |
| ONCOVIN | 1MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | LILLY | Discontinued | 10 Jul 1963 |
| VINCASAR PFS | 1MG/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 17 Jul 1987 |
| VINCREX | 5MG/VIAL | injectable · injection | BRISTOL MYERS SQUIBB | Discontinued | 12 Jul 1988 |
| VINCRISTINE SULFATE PFS | 1MG/ML | injectable · injection | TEVA PHARMS USA | Discontinued | 1 Sep 1999 |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | FRESENIUS KABI USA | Discontinued | 20 Dec 2002 |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | FRESENIUS KABI USA | Discontinued | 28 Oct 2003 |
| MARQIBO KIT | 5MG/5ML (1MG/ML) | injectable, liposomal · intravenous | ACROTECH | Discontinued | 9 Aug 2012 |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | ABRAXIS PHARM | Discontinued | |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | QUAD PHARMS | Discontinued | |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | QUAD PHARMS | Discontinued | |
| VINCRISTINE SULFATE | 1MG/ML | injectable · injection | ABIC | Discontinued | |
| VINCRISTINE SULFATE | 1MG/VIAL | injectable · injection | QUAD PHARMS | Discontinued | |
| VINCRISTINE SULFATE | 2MG/VIAL | injectable · injection | QUAD PHARMS | Discontinued | |
| VINCRISTINE SULFATE | 1MG/VIAL | injectable · injection | HOSPIRA | Discontinued | |
| VINCRISTINE SULFATE | 2MG/VIAL | injectable · injection | HOSPIRA | Discontinued | |
| VINCRISTINE SULFATE | 5MG/VIAL | injectable · injection | HOSPIRA | Discontinued | |
| VINCRISTINE SULFATE | 5MG/VIAL | injectable · injection | QUAD PHARMS | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VINCRISTINE SULFATE INJECTION | 02143305 | 1 MG / ML | SOLUTION · INTRAVENOUS | TEVA CANADA LIMITED |
| VINCRISTINE SULFATE INJECTION USP | 02183013 | 1 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Other specified gliomas of brain; Diffuse large B-cell lymphoma, not otherwise specified; Burkitt lymphoma including Burkitt leukaemia; Lymphoid leukaemia, not elsewhere classified; Langerhans cell histiocytosis; Kaposi sarcoma of unspecified primary site; Rhabdomyosarcoma primary site; Hodgkin lymphoma; Malignant trophoblastic neoplasms of placenta; Follicular lymphoma; Ewing sarcoma of bone or articular cartilage of unspecified sites; Retinoblastoma; Malignant neoplasms of kidney, except renal pelvis
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
Safety signals and safety-related labeling changes
- US FDA 8 Jun 2020 MARQIBO KIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.